Le Lézard
Classified in: Health, Science and technology
Subjects: LAW, PLW

Bio-Techne Files Patent Infringement Lawsuit Against Molecular Instruments


Bio-Techne enforces intellectual property for gold standard RNAscopeŽ ISH technology in spatial biology and clinical applications.

MINNEAPOLIS, Sept. 26, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, today announced that it has taken legal action in the United Kingdom to halt the infringement of its patented RNAscopeŽ ISH technology by Molecular Instruments, Inc.

Advanced Cell Diagnostics, a Bio-Techne brand, owns patents covering various features of its RNAscopeŽ technology. RNAscopeŽ is the gold standard for in situ hybridization (ISH), trusted by researchers around the globe, with a rapidly growing list of over 6,000 peer reviewed publications. With over 40,000 unique RNAscopeŽ ISH catalog probes available in over 400 species and fast, expert custom probe design, researchers have the flexibility to spatially interrogate any gene across a wide array of diseases and tissues with unparalleled sensitivity and specificity.

In its lawsuit filed in the UK Patents Court, Bio-Techne alleges that Molecular Instruments' HCR 3.0 technology infringes Bio-Techne's European Patents (UK) 2,500,439 and 1,910,572. The lawsuit seeks damages and injunctive relief requiring Molecular Instruments to stop infringing Bio-Techne's patents in the United Kingdom.

"Bio-Techne has made substantial investments in the development and application of its RNAscopeŽ technology to advance research discovery and accelerate diagnostic and therapeutic product development," said Chuck Kummeth, President and Chief Executive Officer of Bio-Techne. "Our intellectual property portfolio is foundational to our innovation in the spatial biology detection space, and we are committed to protecting these investments and defending our intellectual property rights."

About Bio-Techne Corporation (NASDAQ: TECH)
Contact: David Clair, Vice President, Investor Relations
[email protected] 
612-656-441

 

SOURCE Bio-Techne Corporation


These press releases may also interest you

at 21:15
NHIT Marks 15th Anniversary of Impact with a White House Health Equity Roundtable and Focus on the Future
The National Health IT Collaborative for the Underserved (NHIT), the first and oldest national non-profit focused on equitable access to health technology for underserved communities and communities of color, celebrated its 15th anniversary today...

at 21:00
Social Anxiety Disorder (SAD) Market Insights, Epidemiology and Market Forecasts, 2032 - Focus on United States, Germany, Spain, Italy, France, United Kingdom and Japan
The "Social Anxiety Disorder (SAD) - Market Insight, Epidemiology and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. The Social Anxiety Disorder (SAD) market report provides current treatment practices, emerging...

at 20:45
Global Continuous Glucose Monitoring (CGM) Solutions Markets Report 2023-2027: Opportunities in Type 2 Diabetic and Non Diabetic Patients Treatment Boost Future Growth Potential
The "Global Continuous Glucose Monitoring Solutions Market, 2027 Forecast" report has been added to  ResearchAndMarkets.com's offering. Technological advancements and strategic partnerships create new opportunities for CGM vendors. The rising...

at 20:40
Kanazawa University research: Enhancing carbon dioxide reduction
Researchers at Kanazawa University report in ACS Nano how ultrathin layers of tin disulfide can be used to accelerate the chemical reduction of carbon dioxide - a finding that is highly relevant for our quest towards a carbon-neutral society....

at 20:15
Global Regenerative Medicines Bone and Joints Research Report 2023: Increasing Product Approvals and Launches & R&D for Stem and Gene Therapies Bodes well for the Sector
The "Regenerative Medicines: Bone and Joint Applications" report has been added to  ResearchAndMarkets.com's offering. The global market for regenerative medicine for bone and joint applications was valued at $9.6 billion in 2022. By technology, this...

at 20:10
UPDATE - Announcing 2023's Cutest Pets on Parliament Hill!
The Canadian Animal Health Institute is thrilled to announce the winners of the inaugural ?Cutest Pets on Parliament Hill Contest'. Parliamentarians, Senators, staffers, and members of the Press Gallery on Parliament Hill, submitted more than 65...

More news about Health...


News published on and distributed by: